Sumi Bez

Sumi Bez

Auto-generated profile, based on publicly available information

Sumi Bez

UK Dementia Research Institute at University College London, London, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2024 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
SFStephanie L. Fowler
Stephanie L. Fowler
TBTiana S. Behr
Tiana S. Behr
ETEmir Turkes
Emir Turkes
DODarragh P. O’Brien
Darragh P. O’Brien
PCPaula Maglio Cauhy
Paula Maglio Cauhy
BRBenjamin Ryskeldi-Falcon
Benjamin Ryskeldi-Falcon
The abnormal assembly of tau protein in neurons is a pathological hallmark of multiple neurodegenerative diseases, including Alzheimer’s disease (AD). Assembled tau associates with extracellular vesicles (EVs) in the central nervous system of individuals with AD, which is linked to its clearance and prion-like propagation. However, the identities of the assembled tau species and EVs, as well as how they associate, are not known. Here, we combined quantitative mass spectrometry, cryo-electron tomography and single-particle cryo-electron microscopy to study brain EVs from individuals with AD. We found tau filaments composed mainly of truncated tau that were enclosed within EVs enriched in endo-lysosomal proteins. We observed multiple filament interactions, including with molecules that tethered filaments to the EV limiting membrane, suggesting selective packaging. Our findings will guide studies into the molecular mechanisms of EV-mediated secretion of assembled tau and inform the targeting of EV-associated tau as potential therapeutic and biomarker strategies for AD.

24 December 2024 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
NWNaoto Watamura
Naoto Watamura
MFMartha S. Foiani
Martha S. Foiani
SBSumi Bez
Sumi Bez
MBMathieu Bourdenx
Mathieu Bourdenx
ASAlessia Santambrogio
Alessia Santambrogio
TSTakaomi C. Saido
Takaomi C. Saido
Tau pathology is a hallmark of several neurodegenerative diseases, including frontotemporal dementia and Alzheimer’s disease. However, the sequence of events and the form of tau that confers toxicity are still unclear, due in large part to the lack of physiological models of tauopathy initiation and progression in which to test hypotheses. We have developed a series of targeted mice expressing frontotemporal-dementia-causing mutations in the humanized MAPT gene to investigate the earliest stages of tauopathy. MAPT Int10+3G>A and MAPT S305N;Int10+3G>A lines show abundant hyperphosphorylated tau in the hippocampus and entorhinal cortex, but they do not develop seed-competent fibrillar structures. Accumulation of hyperphosphorylated tau was accompanied by neurite degeneration, loss of viable synapses and indicators of behavioral abnormalities. Our results demonstrate that neuronal toxicity can occur in the absence of fibrillar, higher-order structures and that tau hyperphosphorylation is probably involved in the earliest etiological events in tauopathies showing isoform ratio imbalance.

30 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SFS. L. Fowler
S. L. Fowler
TBT. S. Behr
T. S. Behr
ETE. Turkes
E. Turkes
PCP. Maglio Cauhy
P. Maglio Cauhy
MFM. S. Foiani
M. S. Foiani
BRB. Ryskeldi-Falcon
B. Ryskeldi-Falcon
SUMMARY: The abnormal assembly of tau protein in neurons is the pathological hallmark of multiple neurodegenerative diseases, including Alzheimer’s disease (AD). In addition, assembled tau associates with extracellular vesicles (EVs) in the central nervous system of patients with AD, which is linked to its clearance and prion-like propagation between neurons. However, the identities of the assembled tau species and the EVs, as well as how they associate, are not known. Here, we combined quantitative mass spectrometry, cryo-electron tomography and single-particle cryo-electron microscopy to study brain EVs from AD patients. We found filaments of truncated tau enclosed within EVs enriched in endo-lysosomal proteins. We observed multiple filament interactions, including with molecules that tethered filaments to the EV limiting membrane, suggesting selective packaging. Our findings will guide studies into the molecular mechanisms of EV-mediated secretion of assembled tau and inform the targeting of EV-associated tau as potential therapeutic and biomarker strategies for AD.

31 July 2026 in Science Advances
Verified
Journal Article
Closed access
ETEliona Tsefou
Eliona Tsefou
SBSumi Bez
Sumi Bez
TBTimothy J. Y. Birkle
Timothy J. Y. Birkle
MFMartha Foiani
Martha Foiani
NWNaoto Watamura
Naoto Watamura
KDKaren E. Duff
Karen E. Duff
The accumulation of pathological four-repeat (4R) tau is central to several frontotemporal dementia (FTD) subtypes, but human neuronal models amenable to high-throughput screening of 4R tau–targeting therapies remain very limited. To address this, we developed induced pluripotent stem cell (iPSC)–derived i 3 Neuron (i 3 N) lines expressing >75% 4R tau, driven by FTD splice-shifting mutations (Ser 305 Asn; S305N or S305N/IVS10 + 3). These neurons develop hyperphosphorylated tau and demonstrate somatodendritic mislocalization. These i 3 N neurons develop endogenous seed-competent tau and present pentameric formyl thiophene acetic acid–(pFTAA)-positive tau assemblies after 28 days in culture. For scalable screening, we CRISPR-engineered an HiBiT luminescence tag at the endogenous MAPT locus into the S305N/IVS10 + 3 iPSC line, enabling precise quantification of tau levels and pharmacological responses. The model responded predictably to compounds affecting tau clearance, demonstrating its suitability for drug discovery. Overall, this i 3 N platform recapitulates key features of 4R tauopathy and provides a robust system to identify therapeutic modulators of pathological tau.

12 March 2026 in Research Square
Verified
Preprint
Open access
PDF file
MFMartha Foiani
Martha Foiani
RNRaja Nirujogi
Raja Nirujogi
NWNaoto Watamura
Naoto Watamura
SBSumi Bez
Sumi Bez
ETEliona Tsefou
Eliona Tsefou
KDKaren Duff
Karen Duff
Tau pathology underlies a broad spectrum of neurodegenerative disorders, collectively termed tauopathies, yet these diseases exhibit striking heterogeneity in their biological mechanisms and clinical outcomes. The basis for this heterogeneity remains poorly understood. Here, we address this question using knock-in mouse models expressing two distinct frontotemporal dementia-associated tau mutations to define how different tau variants drive divergent pathogenic programs in vivo. We find that the two mutations give rise to fundamentally different trajectories of tau pathogenesis. One trajectory is marked by progressive tau hyperphosphorylation and cytoskeletal destabilization occurring in the absence of detectable tau seed formation. In contrast, an alternative trajectory is characterized by tau hypophosphorylation, early seed formation, and alterations in nucleotide metabolism and chromatin organization, without overt cytoskeletal disruption. With aging, tau in this latter pathway transitions to a hyperphosphorylated state and forms mature fibrillar aggregates. Genetic enhancement of β-amyloid selectively accelerates fibril formation, particularly in the model exhibiting early seeding. Together, these findings demonstrate that distinct tau mutations can engage separable pathogenic mechanisms, providing a biological framework for the heterogeneity observed across tauopathies and highlighting the need for mechanism-informed therapeutic strategies and patient stratification.